Protocol for analyses of adverse event data from randomized controlled trials of statin therapy

Publication date: Available online 28 January 2016 Source:American Heart Journal Author(s): C. Reith, L. Blackwell, J. Emberson, B. Mihaylova, J. Armitage, J. Fulcher, A. Keech, J. Simes, C. Baigent, R. Collins The Cholesterol Treatment Trialists’ (CTT) Collaboration was originally established to conduct individual patient data meta-analyses of major vascular events, cause-specific mortality and site-specific cancers in large, long-term, randomized trials of statin therapy (and other cholesterol-modifying treatments). The results of the trials of statin therapy, and their associated meta-analyses, have shown that statins significantly reduce the risk of major vascular events without any increase in the risk of non-vascular causes of death or of site-specific cancer, but do produce small increases in the incidence of myopathy, diabetes, and, probably, haemorrhagic stroke. The CTT Collaboration has not previously sought data on other outcomes, and so a comprehensive meta-analysis of all adverse events recorded in each of the eligible trials has not been conducted. This protocol prospectively describes plans to extend the CTT meta-analysis dataset so as to provide a more complete understanding of the nature and magnitude of any other effects of statin therapy.
Source: American Heart Journal - Category: Cardiology Source Type: research